Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cyptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles

Robert W. Maitta, Kausik Datta, Qing Chang, Robin X. Luo, Bradley Witover, Krishanthi Subramaniam, Liise-anne Pirofski

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

The features of protective murine antibodies to the Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan (GXM) have been rigorously investigated; however, the characteristics of protective human antibodies to GYM have not been defined. We produced monoclonal antibodies (MAbs) from XenoMouse mice (transgenic mice that express human immunoglobulin M [IgM], IgG2, and κ) which were immunized with a C. neoformans serotype D strain 24067 GXM-diphtheria toxoid conjugate. This study reports the specificity and efficacy of three human IgM MAbs, G14, G15, and G19, generated from these mice. Each MAb was specific for GXM, but G14 and G19 had different specificity based on their binding to serotype A strain H99 and SB4 GXMs, to which G15 did not bind. Nucleic acid sequence analysis revealed that G15 uses VH3-64 in the germ line configuration. G14 and G19 use VH6-1, which has somatic mutations. All of the MAbs use Vκ DPK22/A27. Studies of MAb efficacy in BALB/c mice showed that administration of 0.1 mg, but not 1 or 0.01 mg, of G15 prolonged survival against lethal C. neoformans strain 24067 challenge, whereas G14 and G19 were not protective at any dose. This panel of MAbs illustrates that serotype D GXM has epitopes that elicit human antibodies that can be either protective or nonprotective. Our findings suggest that VH. gene use may influence GXM specificity and efficacy, and they provide insights into the possible contribution that VH gene use may have in resistance and susceptibility to cryptococcosis.

Original languageEnglish (US)
Pages (from-to)4810-4818
Number of pages9
JournalInfection and Immunity
Volume72
Issue number8
DOIs
StatePublished - Aug 2004

Fingerprint

Immunoglobulin M
Monoclonal Antibodies
Cryptococcus neoformans
Genes
Antibodies
Diphtheria Toxoid
Cryptococcosis
Germ Cells
Nucleic Acids
Transgenic Mice
Polysaccharides
Sequence Analysis
Epitopes
Immunoglobulin G
glucuronoxylomannan
Mutation
Survival
Serogroup

ASJC Scopus subject areas

  • Immunology

Cite this

Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cyptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles. / Maitta, Robert W.; Datta, Kausik; Chang, Qing; Luo, Robin X.; Witover, Bradley; Subramaniam, Krishanthi; Pirofski, Liise-anne.

In: Infection and Immunity, Vol. 72, No. 8, 08.2004, p. 4810-4818.

Research output: Contribution to journalArticle

Maitta, Robert W. ; Datta, Kausik ; Chang, Qing ; Luo, Robin X. ; Witover, Bradley ; Subramaniam, Krishanthi ; Pirofski, Liise-anne. / Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cyptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles. In: Infection and Immunity. 2004 ; Vol. 72, No. 8. pp. 4810-4818.
@article{c1d344ef76ae4c08a5f0f35abf6db24c,
title = "Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cyptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles",
abstract = "The features of protective murine antibodies to the Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan (GXM) have been rigorously investigated; however, the characteristics of protective human antibodies to GYM have not been defined. We produced monoclonal antibodies (MAbs) from XenoMouse mice (transgenic mice that express human immunoglobulin M [IgM], IgG2, and κ) which were immunized with a C. neoformans serotype D strain 24067 GXM-diphtheria toxoid conjugate. This study reports the specificity and efficacy of three human IgM MAbs, G14, G15, and G19, generated from these mice. Each MAb was specific for GXM, but G14 and G19 had different specificity based on their binding to serotype A strain H99 and SB4 GXMs, to which G15 did not bind. Nucleic acid sequence analysis revealed that G15 uses VH3-64 in the germ line configuration. G14 and G19 use VH6-1, which has somatic mutations. All of the MAbs use Vκ DPK22/A27. Studies of MAb efficacy in BALB/c mice showed that administration of 0.1 mg, but not 1 or 0.01 mg, of G15 prolonged survival against lethal C. neoformans strain 24067 challenge, whereas G14 and G19 were not protective at any dose. This panel of MAbs illustrates that serotype D GXM has epitopes that elicit human antibodies that can be either protective or nonprotective. Our findings suggest that VH. gene use may influence GXM specificity and efficacy, and they provide insights into the possible contribution that VH gene use may have in resistance and susceptibility to cryptococcosis.",
author = "Maitta, {Robert W.} and Kausik Datta and Qing Chang and Luo, {Robin X.} and Bradley Witover and Krishanthi Subramaniam and Liise-anne Pirofski",
year = "2004",
month = "8",
doi = "10.1128/IAI.72.8.4810-4818.2004",
language = "English (US)",
volume = "72",
pages = "4810--4818",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "8",

}

TY - JOUR

T1 - Protective and nonprotective human immunoglobulin M monoclonal antibodies to Cyptococcus neoformans glucuronoxylomannan manifest different specificities and gene use profiles

AU - Maitta, Robert W.

AU - Datta, Kausik

AU - Chang, Qing

AU - Luo, Robin X.

AU - Witover, Bradley

AU - Subramaniam, Krishanthi

AU - Pirofski, Liise-anne

PY - 2004/8

Y1 - 2004/8

N2 - The features of protective murine antibodies to the Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan (GXM) have been rigorously investigated; however, the characteristics of protective human antibodies to GYM have not been defined. We produced monoclonal antibodies (MAbs) from XenoMouse mice (transgenic mice that express human immunoglobulin M [IgM], IgG2, and κ) which were immunized with a C. neoformans serotype D strain 24067 GXM-diphtheria toxoid conjugate. This study reports the specificity and efficacy of three human IgM MAbs, G14, G15, and G19, generated from these mice. Each MAb was specific for GXM, but G14 and G19 had different specificity based on their binding to serotype A strain H99 and SB4 GXMs, to which G15 did not bind. Nucleic acid sequence analysis revealed that G15 uses VH3-64 in the germ line configuration. G14 and G19 use VH6-1, which has somatic mutations. All of the MAbs use Vκ DPK22/A27. Studies of MAb efficacy in BALB/c mice showed that administration of 0.1 mg, but not 1 or 0.01 mg, of G15 prolonged survival against lethal C. neoformans strain 24067 challenge, whereas G14 and G19 were not protective at any dose. This panel of MAbs illustrates that serotype D GXM has epitopes that elicit human antibodies that can be either protective or nonprotective. Our findings suggest that VH. gene use may influence GXM specificity and efficacy, and they provide insights into the possible contribution that VH gene use may have in resistance and susceptibility to cryptococcosis.

AB - The features of protective murine antibodies to the Cryptococcus neoformans capsular polysaccharide glucuronoxylomannan (GXM) have been rigorously investigated; however, the characteristics of protective human antibodies to GYM have not been defined. We produced monoclonal antibodies (MAbs) from XenoMouse mice (transgenic mice that express human immunoglobulin M [IgM], IgG2, and κ) which were immunized with a C. neoformans serotype D strain 24067 GXM-diphtheria toxoid conjugate. This study reports the specificity and efficacy of three human IgM MAbs, G14, G15, and G19, generated from these mice. Each MAb was specific for GXM, but G14 and G19 had different specificity based on their binding to serotype A strain H99 and SB4 GXMs, to which G15 did not bind. Nucleic acid sequence analysis revealed that G15 uses VH3-64 in the germ line configuration. G14 and G19 use VH6-1, which has somatic mutations. All of the MAbs use Vκ DPK22/A27. Studies of MAb efficacy in BALB/c mice showed that administration of 0.1 mg, but not 1 or 0.01 mg, of G15 prolonged survival against lethal C. neoformans strain 24067 challenge, whereas G14 and G19 were not protective at any dose. This panel of MAbs illustrates that serotype D GXM has epitopes that elicit human antibodies that can be either protective or nonprotective. Our findings suggest that VH. gene use may influence GXM specificity and efficacy, and they provide insights into the possible contribution that VH gene use may have in resistance and susceptibility to cryptococcosis.

UR - http://www.scopus.com/inward/record.url?scp=3342969259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3342969259&partnerID=8YFLogxK

U2 - 10.1128/IAI.72.8.4810-4818.2004

DO - 10.1128/IAI.72.8.4810-4818.2004

M3 - Article

VL - 72

SP - 4810

EP - 4818

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 8

ER -